Form D · Biotechnology
Illexcor Therapeutics, Inc.
Henrico, VA · CIK 0002132799
Offering snapshot reported May 8, 2026 · SEC filing
- Reported sold
- $13M Offering amount: $69M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $1M Reported outside-investor minimum
- First sale
- Apr 15, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 8, 2026 | Initial | $13,000,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-583301
Total amount remaining to be sold is subject to milestones in agreement.
Source: Form D, filed May 8, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew N Fleischman | Director, Executive |
| Timothy E Ladin | Executive |
| Ted Love | Director |
| Giovanni Mariggi | Director |
| Maneka Mirchandaney | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11924 Evening Loop
Henrico, VA, 23233
Henrico, VA, 23233